NCT01215890已完成4 期
A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
The occurrence of bone loss in Crohn's disease patients is an important clinical problem for both patients with and without active disease. While therapy does exist for treatment and prevention of low BMD, evidence of its efficacy in Crohn's disease patients is lacking. The current standard of therapy in Canada for the treatment of osteoporosis is etidronate, with adequate calcium and vitamin D supplementation.
The primary objective of the study is to assess the efficacy of risedronate, compared to placebo, administered once-weekly, in the treatment of low BMD of the spine and hip in patients with Crohn's disease at 12 months, based on an intention-to-treat analysis.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who are 18 years of age, or older.
- •Crohn's disease, as documented by clinical, radiologic, endoscopic or histologic examination.
- •Osteoporosis (T score less than -2.5) or osteopenia (T score between -1.0 and -2.5), as determined by dual energy X-ray absorptiometry.
排除标准
- •Known bone disorders other than osteoporosis (such as hyperparathyroidism, Paget's disease, renal osteodystrophy and documented osteomalacia)
- •Abnormal thyroid function. Those patients on thyroxine replacement must not have had a change in dose in the two months prior to prospective data collection program entry
- •Clinically significant renal impairment (serum creatinine ≥ 2x normal).
- •Clinical Short Bowel Syndrome
- •Patients on total parenteral or enteral nutrition
- •Spinal anatomy that would not allow adequate assessment of lateral spine using DEXA
- •Patients who had received:
- •previous bisphosphonate therapy
- •fluoride supplement in the 24 months prior to entry
- •calcium supplements of more than 1.0g/day in the 6 months prior to entry
- •vitamin D supplements greater than 1000 IU/day in the 6 months prior to entry
- •calcitonin in the 3 months prior to entry
- •Females on hormone replacement therapy who do not agree to continue the therapy for the duration of the prospective data collection program
- •Men on testosterone who do not agree to continue it for the duration of the prospective data collection program
- •Pregnancy or women who are breastfeeding
研究组 & 干预措施
risedronate plus calcium and viamin D
Active Comparator
干预措施: risedronate (Drug)
placebo plus clacium and vitamin D
Placebo Comparator
干预措施: placebo (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
The CROCO Study: CROhn's Disease COhort StudyCrohn DiseaseNCT05420233GLSMED Learning Health S.A.533
已完成
不适用
Study to Determine the Prevalence of Osteoporosis in Patients With Advanced Prostate Cancer Treated With Hormonal ManipulationOsteoporosisProstate CancerNCT00124410AHS Cancer Control Alberta100
已完成
不适用
Development and Validation of a Nomogram for Predicting Surgery in Newly-diagnosed Crohn's Disease: a Retrospective Cohort StudyNewly-diagnosed Crohn's DiseaseNCT06457035First Affiliated Hospital, Sun Yat-Sen University490
招募中
2 期
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseaseCrohn's DiseaseNCT06548542AbbVie540
Unknown
不适用
Observational Prospective Study to Identify Intestinal Microbial Profiles in Newly Diagnosed Crohn's Disease PatientsCrohn DiseaseNCT06324591Meyer Children's Hospital IRCCS30